X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bapineuzumab (119) 119
index medicus (81) 81
alzheimer's disease (73) 73
humans (63) 63
neurosciences (47) 47
immunotherapy (43) 43
alzheimer disease - drug therapy (41) 41
solanezumab (40) 40
clinical neurology (35) 35
female (31) 31
trials (30) 30
male (28) 28
a-beta (23) 23
aged (21) 21
dementia (21) 21
immunization (21) 21
alzheimer’s disease (20) 20
alzheimers-disease (19) 19
antibodies, monoclonal, humanized - therapeutic use (19) 19
pharmacology & pharmacy (19) 19
amyloid-beta (18) 18
mouse model (18) 18
peptide (18) 18
amyloid beta-peptides - immunology (17) 17
animals (17) 17
clinical trials (17) 17
imaging abnormalities (17) 17
magnetic resonance imaging (17) 17
middle aged (16) 16
brain (15) 15
amyloid beta-peptides - metabolism (14) 14
pathology (14) 14
aged, 80 and over (13) 13
alzheimers disease (13) 13
antibodies (13) 13
beta-amyloid (13) 13
alzheimer disease - immunology (12) 12
alzheimer disease - metabolism (12) 12
amyloid (12) 12
monoclonal antibodies (12) 12
research (12) 12
alzheimer disease - pathology (11) 11
biomarkers (11) 11
clinical trial (11) 11
dose-response relationship, drug (11) 11
double-blind (11) 11
mice (11) 11
tau (11) 11
treatment outcome (11) 11
β-amyloid (11) 11
amyloid beta (10) 10
antibodies, monoclonal, humanized - adverse effects (10) 10
cognitive ability (10) 10
drug therapy (10) 10
edema (10) 10
safety (10) 10
alzheimer disease (9) 9
alzheimer disease - diagnostic imaging (9) 9
amyloid beta-peptides - antagonists & inhibitors (9) 9
apolipoprotein-e (9) 9
care and treatment (9) 9
cerebral amyloid angiopathy (9) 9
mice, transgenic (9) 9
mild cognitive impairment (9) 9
oligomers (9) 9
passive immunotherapy (9) 9
severity of illness index (9) 9
alzheimer disease - therapy (8) 8
amyloid precursor protein (8) 8
brain - metabolism (8) 8
clinical trials as topic (8) 8
medicine, research & experimental (8) 8
neurology (8) 8
abridged index medicus (7) 7
alzheimer disease - genetics (7) 7
disease models, animal (7) 7
double-blind method (7) 7
follow-up (7) 7
immunotherapy - methods (7) 7
inflammation (7) 7
monoclonal antibody (7) 7
neurodegeneration (7) 7
neurodegenerative diseases (7) 7
neurofibrillary tangles (7) 7
phase-3 trials (7) 7
protein (7) 7
proteins (7) 7
amyloid-β (6) 6
an1792 (6) 6
antibodies, monoclonal - therapeutic use (6) 6
article (6) 6
beta (6) 6
biotechnology & applied microbiology (6) 6
brain - drug effects (6) 6
cerebrospinal-fluid (6) 6
clinical-trials (6) 6
diagnosis (6) 6
dimebon (6) 6
effusion (6) 6
gamma-secretase inhibitor (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Neurology, ISSN 0028-3878, 04/2018, Volume 90, Issue 21, pp. E1889 - E1897
OBJECTIVETo evaluate the safety and efficacy of crenezumab in patients with mild to moderate Alzheimer disease (AD). METHODSIn this phase 2 trial, 431 patients... 
DEMENTIA | CLINICAL-TRIALS | A-BETA | NEURODEGENERATION | ANTIBODY | BAPINEUZUMAB | ASSESSMENT SCALE | PNEUMONIA | OLIGOMERS | CLINICAL NEUROLOGY | 322
Journal Article
Nature, ISSN 0028-0836, 08/2016, Volume 537, Issue 7618, pp. 50 - 56
Journal Article
Alzheimer's Research and Therapy, ISSN 1758-9193, 12/2015, Volume 7, Issue 1, pp. 1 - 13
Introduction: CAD106 is designed to stimulate amyloid-beta (A beta)-specific antibody responses while avoiding T-cell autoimmune responses. The CAD106... 
ANTIBODIES | IMMUNIZATION | TRIALS | DEMENTIA | MOUSE | PATHOLOGY | BAPINEUZUMAB | MODEL | NEUROSCIENCES | CLINICAL NEUROLOGY
Journal Article
by Xing, HY and Li, B and Peng, D and Wang, CY and Wang, GY and Li, P and Le, YY and Wang, JM and Ye, G and Chen, JH
PLOS ONE, ISSN 1932-6203, 06/2017, Volume 12, Issue 6
Senile plaques consisting of Amyloid-beta (4) peptides, in particular A beta(1-42), are the hallmark of Alzheimer's disease (AD) and have been the primary... 
PHASE-3 TRIALS | TARGET | PEPTIDES | AMYLOID-BETA | MULTIDISCIPLINARY SCIENCES | A-BETA | THERAPIES | BAPINEUZUMAB | BINDING | BURDEN | BRAIN
Journal Article
Alzheimer's Research & Therapy, ISSN 1758-9193, 2016, Volume 8, Issue 1, p. 18
Journal Article
Journal Article
Expert Opinion on Investigational Drugs, ISSN 1354-3784, 06/2017, Volume 26, Issue 6, pp. 735 - 739
Introduction: There are dozens of drugs in development for AD with billions of dollars invested. Despite the massive investment in AD drugs and a burgeoning... 
secretase inhibitors | Amyloid | clinical trials | Alzheimer's | dimebon | monoclonal antibodies | PHASE-3 TRIALS | SOLANEZUMAB | PHARMACOLOGY & PHARMACY | BAPINEUZUMAB | Alzheimer Disease - drug therapy | Clinical Trials as Topic | Drugs, Investigational - pharmacology | Humans | Treatment Failure | Drug Design
Journal Article
BRAIN, ISSN 0006-8950, 07/2019, Volume 142, Issue 7, pp. 2113 - 2126
We performed a 15-year post-mortem neuropathological follow-up of patients in the first trial of amyloid-beta immunotherapy for Alzheimer's disease. Twenty-two... 
TRIALS | AN1792 | IMAGING ABNORMALITIES | TAU | ASSOCIATION GUIDELINES | PATHOLOGY | BAPINEUZUMAB | NEUROSCIENCES | PEPTIDE | CLINICAL NEUROLOGY | amyloid-beta | NATIONAL INSTITUTE | immunotherapy | dementia | Alzheimer's disease | neuropathology
Journal Article
The American Journal of Geriatric Psychiatry, ISSN 1064-7481, 12/2019, Volume 27, Issue 12, pp. 1428 - 1432
Correctly diagnosing early symptomatic Alzheimer disease in the context of multinational clinical trials poses a significant challenge. Subjective complaints... 
clinical trials | mild cognitive impairment | cut-off scores | Alzheimer disease | MILD | PSYCHIATRY | SOLANEZUMAB | GERONTOLOGY | BAPINEUZUMAB | GERIATRICS & GERONTOLOGY
Journal Article
New England Journal of Medicine, ISSN 0028-4793, 01/2018, Volume 378, Issue 4, pp. 321 - 330
Journal Article
NEW ENGLAND JOURNAL OF MEDICINE, ISSN 0028-4793, 06/2019, Volume 380, Issue 24, pp. 2307 - 2316
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 02/2019, Volume 105, Issue 2, pp. 436 - 447
Clinical observations of patients with chronic diseases are often restricted in terms of duration. Therefore, obtaining a quantitative and comprehensive... 
TRIALS | SCORE | ALZHEIMERS-DISEASE | SOLANEZUMAB | OPEN ACCESS SERIES | MRI DATA | VALIDATION | PHARMACOLOGY & PHARMACY | HYPOTHETICAL MODEL | BAPINEUZUMAB | APOLIPOPROTEIN-E | Research
Journal Article